Articles tagged with Amyloids
Scientists at the University of Liverpool and Callaghan Innovation have developed a new chemical approach to harness the natural ability of complex sugars to treat Alzheimer's disease. They produced a library of sugars called heparan sulphates, which can inhibit an enzyme that creates small proteins in the brain causing memory loss.
A team of researchers at Lund University has identified the molecular mechanism behind the formation of Alzheimer's disease-causing plaques. The discovery reveals a self-perpetuating and autocatalytic process that creates cell-killing formations, potentially paving the way for new treatments targeting early stages of the disease.
Researchers suggest targeting APPL protein for new Alzheimer's drugs, as it ensures optimal communication between brain cells. This approach may be more effective than solely focusing on breaking down Amyloid beta.
Researchers at Pitt Public Health have found that an anti-cancer drug, bexarotene, significantly improves cognitive deficits in mice with Alzheimer's gene mutations. The study suggests a possible new therapeutic treatment for Alzheimer's disease, although the exact mechanism of action remains unclear.
Researchers found that an anti-cancer drug, bexarotene, did not reduce amyloid plaques in the brains of mice, despite initial claims of its effectiveness in reversing Alzheimer's-like symptoms. The study suggests that further research is needed to understand the nuances of this potential treatment.
Scientists have reevaluated the role of the APOE gene in Alzheimer's disease, finding minimal interaction between APOE and amyloid beta in cerebrospinal fluid. This suggests a need to rethink therapeutic strategies targeting APOE, as current approaches may not be effective.
Researchers have found that high-frequency bursts in the brain improve the ratio of healthy amyloid-beta 40 to unhealthy 42, potentially protecting against Alzheimer's. The study suggests environmental changes and experiences can modify synapse properties, leading to increased production of amyloid-beta 40.
Researchers have discovered that brain damage in Alzheimer's disease is caused by the overactivation of an enzyme called AMPK, leading to the loss of synapses and neuron damage. Blocking this enzyme in mouse models prevented further neuronal loss.
Scientists have identified several genes linked to the tau protein, which is found in brain tangles that develop in Alzheimer's patients. The findings may help provide targets for a different class of drugs that could be used for treatment.
Recent studies from Stanford University School of Medicine have found that small portions of amyloid-forming proteins can alleviate symptoms in mice with multiple sclerosis and Alzheimer's disease. The research suggests a radical new idea: full-length, amyloid-forming proteins may be produced by the body as protective forces.
Researchers found that long-term treatment with carmustine decreased amyloid beta levels by 75% in a mouse model of Alzheimer's disease. Carmustine, a cancer treatment, shows promise as a potential drug for reducing Alzheimer's symptoms.
A recent study published in JAMA Neurology found that unmedicated adults with hypertension and a genetic risk factor for Alzheimer's disease have higher amyloid plaque levels than other groups. Controlling hypertension may significantly decrease the risk of developing amyloid deposits, even in those with genetic risk.
A new study found that prolonged exposure to an enriched environment activates brain receptors, preventing amyloid beta protein from weakening nerve cell communication. This provides a molecular mechanism for why a richer environment can help lessen the memory-eroding effects of Alzheimer's disease.
Researchers at the University of Michigan have discovered that green tea extract can prevent the misfolding of specific proteins in the brain, which is associated with Alzheimer's disease. The study found that a molecule in green tea, EGCG, prevented aggregate formation and broke down existing structures in proteins containing metals.
Using both familial and sporadic AD iPSCs, the researchers discovered that pathogenesis differed between individual AD patients. They found stress phenotypes associated with intracellular amyloid beta oligomers and attenuated these phenotypes with docosahexaenoic acid (DHA) treatment.
Researchers found that vitamin D3 and omega-3 fatty acids improved the immune system's ability to clear amyloid plaques from the brain. The study identified key genes and signaling networks regulated by these substances, which may help control inflammation and improve plaque clearance.
Researchers have identified a key step in the Alzheimer's disease pathway that can be interrupted using green tea and red wine extracts. The study, published in the Journal of Biological Chemistry, offers potential new targets for developing drugs to treat the disease.
A new study reveals that amyloid peptides build-up in brain's blood vessels accelerates cognitive decline by limiting oxygen-rich blood and nutrients. Researchers identify CD36 as a key protein in the buildup of Aβ40 in blood vessels, promoting cerebral amyloid angiopathy (CAA).
The Society of Nuclear Medicine and Molecular Imaging has published the first guidelines for brain amyloid imaging in Alzheimer's disease, providing a framework for healthcare practitioners to determine when to order this test. The guidelines emphasize that amyloid PET imaging should be used judiciously, particularly among elderly indi...
Researchers have discovered a key link between inflammation and Alzheimer's disease progression. The study suggests that drugs targeting IL-1 beta production may provide benefits for patients with Alzheimer's. The findings point to the possibility of developing new treatments by disrupting the production of this pro-inflammatory cytokine.
Researchers have identified a molecular pathway driving Alzheimer's disease progression, revealing new targets for drug discovery. The study found that clusterin acts to switch on a signalling pathway associated with tau tangle formation and cognitive defects.
Researchers discovered that yeast protein Hsp104 can break up both amyloid fibrils and disordered protein clumps, with different requirements for stability. This finding offers a new approach to eliminate toxic clumps linked with neurodegenerative diseases.
Researchers at UCLA have developed a molecular compound called CLR01 that breaks up toxic protein aggregations in a mouse model, clearing amyloid-beta and tau aggregates and protecting neurons' synapses. The compound has shown high safety and efficacy in treating Alzheimer's disease.
Neutrophil extracellular traps (NETs) release DNA-made traps that break down amyloid fibrils into smaller toxic pieces. This process is linked to the aggravation of amyloidosis, a group of clinical syndromes characterized by deposits of amyloid fibrils throughout the body.
Scientists have developed fluorescent probes that change color depending on the type of amyloid they encounter, offering hope for differentiating between related brain disorders. The technology has been licensed for commercial development of diagnostic tests.
Experts from NYU Langone Medical Center will present research on non-invasive evaluation of tau targeted immunotherapy, physician intention to screen for dementia, and remission of pre-mild cognitive impairment. These studies aim to improve diagnosis and treatment of Alzheimer's disease.
Researchers at UCSB used computer simulations to understand the formation of toxic entities in the brain, finding that small oligomer molecules may be responsible for the onset of the disease. These findings suggest new diagnostic and treatment options, including peptide-based inhibitors.
A study published in PLoS Biology describes a way to break apart beneficial amyloid fibers that can play protective roles in the brain. Human cells have the necessary machinery to clear these fibers, which could lead to new treatments for neurodegenerative diseases.
Researchers have identified a mechanism by which small heat shock proteins collaborate with other molecular chaperones to disassemble amyloid fibers. This activity could lead to the development of therapeutic applications for neurodegenerative disorders, such as Parkinson's disease.
Researchers at CCNY found that a single gene forms a common link between diabetes and Alzheimer's disease, affecting the insulin pathway. The finding could point to a therapeutic target for both diseases.
Researchers have made significant breakthroughs in Alzheimer's disease detection using molecular imaging technology, which can identify beta-amyloid plaques in the brain. Studies show that high levels of amyloid binding are associated with an 80% chance of developing Alzheimer's disease within two years.
Researchers at Vanderbilt University discovered a new therapeutic strategy to reduce amyloid-beta production in Alzheimer's disease. By understanding how cholesterol binds to the amyloid precursor protein, they found that blocking this interaction could prevent amyloid-beta generation and treatment of dementia.
The study reveals that tafamidis works by stabilizing the transthyretin (TTR) protein tetramer, preventing it from aggregating into amyloids. This stabilization prevents nerve destruction in polyneuropathy patients and delays disease progression.
Researchers discovered that astrocytes, which normally nourish and protect neurons, deliver a lethal package containing ceramide and PAR-4 when neurons start producing excessive amyloid protein. This process may contribute to brain-cell death and shrinkage in Alzheimer's disease.
UC Davis researchers have discovered novel compounds that disrupt amyloid formation and reduce inflammation in neurons, potentially preventing or delaying Alzheimer's disease damage. The spin-labeled fluorene compounds demonstrate excellent detection of amyloid and anti-inflammatory properties.
A meta-analysis of 13 studies found a significant association between lower Aβ42: Aβ40 ratios and development of Alzheimer disease and dementia. The analysis suggests that measuring this ratio may have value in predicting the risk for later development of dementia or AD.
Researchers at the University of Rochester Medical Center have developed a compound that targets RAGE, a molecular actor involved in Alzheimer's disease. The compound, FPS-ZM1, reverses amyloid deposits, restores brain blood flow, and improves learning capabilities in mice.
Researchers discovered that vitamin D3 activates key genes and cellular signaling networks to stimulate the immune system to clear amyloid-beta protein from the brain. The study provides new insights into the potential therapeutic benefits of vitamin D3 for Alzheimer's disease treatment.
Researchers found that curcumin prolongs the lives of fruit flies with Alzheimer's symptoms by up to 75% and maintains their mobility. However, it did not dissolve or decrease the amyloid plaque, but instead accelerated its formation by reducing precursor forms.
Research suggests that disrupted sleep patterns may be associated with the build-up of amyloid plaques in the brains of people without memory problems. The study found that participants who woke up more than five times per hour and slept inefficiently were more likely to have these markers.
Researchers discover bexarotene rapidly clears amyloid from the brain and reverses cognitive deficits in mouse models of Alzheimer's disease. The results show significant promise for a new therapy, with more than half of amyloid plaques cleared within 72 hours.
Researchers have developed a non-invasive method to diagnose Alzheimer's disease using infrared analysis of white blood cells. The technique distinguishes between mild and moderate stages of the disease, allowing for reliable early diagnosis.
Researchers at Temple University have discovered a protein that regulates amyloid beta production and controls a biochemical chain reaction linked to Alzheimer's development. The protein, 12/15-Lipoxygenase, targets Beta secretase (BACE-1), an enzyme key to amyloid plaque formation.
A new study reveals that people with no symptoms of Alzheimer's who engaged in cognitively stimulating activities throughout their lives had fewer deposits of beta-amyloid, a destructive protein that is the hallmark of the disease. Lifelong cognitive engagement may affect a primary pathological process in the disease, suggesting potent...
Researchers have discovered that myocilin deposits can lead to vision loss in glaucoma patients. The study, published in the Journal of Molecular Biology, explores one of the molecular origins of glaucoma and potentially leads to new treatments.
Researchers identified a series of synthetic compounds that interfere with the self-assembly of amyloid beta peptides, satisfying an initial condition for Alzheimer's treatment. Disordered peptide structure controls interactions with active compounds.
A study by University of South Florida researchers found that elevated levels of an amyloid precursor protein fragment in the blood may explain aberrations in immune cell populations and function. The findings suggest that the protein fragment could be both a biomarker for autism and a new research target.
Researchers found that mice with high amyloid burden experienced significant brain inflammation after receiving the vaccine, while those with lower amyloid burdens showed a significant benefit. The study suggests that vaccines may work best for patients with early disease and lower amyloid burden.
A small study found that gantenerumab, a medication for Alzheimer's disease, reduced brain amyloid levels. The treatment led to dose-dependent amyloid reduction in patients with mild-to-moderate AD.
A daily pattern of rising and falling amyloid beta levels in spinal fluid echoes the sleep cycle, with younger individuals exhibiting stronger highs and lows. As people age, this pattern flattens, potentially providing an opportunity for the body to clear away the Alzheimer's marker.
Researchers have identified a way to reduce beta-amyloid in mouse brains with AD, suggesting that activating ABCC1 transport protein could impede amyloid plaque formation. The approach uses thiethylperazine to activate ABC transporters and has potential for treating Alzheimer's disease.
Researchers at Scripps Research Institute have identified chemical compounds that prevent the abnormal aggregation of the TTR protein, holding it together in its functional form. The compounds have the potential to help hundreds of thousands of people affected by TTR-related amyloid diseases or at risk for them.
Researchers at the University of Leeds have identified an antibiotic that can prevent the formation of amyloid fibrils in proteins. The discovery could lead to new treatments for diseases such as Alzheimer's, Parkinson's, and Type II diabetes.
Blocking a transport pathway through brain cells offers new prospects for preventing Alzheimer's disease development. Researchers discovered that the amyloid beta precursor protein and beta secretase enzyme follow different paths, leading to the formation of amyloid plaques.
The investigational amyloid imaging agent [18F]Flutemetamol showed highly consistent image interpretation and comparable in vitro binding to Pittsburgh Compound-B, according to recent clinical research data. Flutemetamol is being studied for the detection of beta amyloid using PET brain scans.
A study found that participants with high levels of amyloid plaques, a hallmark of Alzheimer's, had twice the typical annual rate of falls for their age group. This suggests that falls may be an early indicator of Alzheimer's disease in people with preclinical symptoms.
Researchers found abnormal tau tangles and amyloid-beta plaques in survivors years after a single TBI, suggesting a potential link between the two conditions. The study suggests that a single TBI may initiate long-term neurodegenerative processes, offering new insights into the development of Alzheimer's disease.
Researchers from NYU Langone Medical Center presented new research at the 2011 Alzheimer's Association International Conference. The study found that retired NFL players are more likely to experience mild cognitive impairment than expected, suggesting a possible link between repetitive head trauma and late-life cognitive disorders. Add...
Rice University researchers have created a metallic molecule that becomes strongly photoluminescent when it attaches to amyloid fibrils, which form plaques in the brains of Alzheimer's patients. This breakthrough technique has the potential to improve the design of medications to treat the devastating disease.
Researchers found that vitamin D injections improved the removal of amyloid beta from the brain of mice, suggesting a potential therapeutic target for preventing Alzheimer's disease. Transporter proteins at the blood CSF barrier also play a crucial role in removing amyloid beta from the brain.